Circulating tumour cells - Monitoring treatment response in prostate cancer

Nature Reviews Clinical Oncology

Volumn 11, Issue 7, 2014, Pages 401-412

  Miyamoto, David T ^a   Sequist, Lecia V ^a   Lee, Richard J ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BIOLOGICAL MARKER; EPITHELIAL CELL ADHESION MOLECULE; KI 67 ANTIGEN; MEMBRANE ANTIGEN; PROSTATE SPECIFIC ANTIGEN; CELL DNA; CELL MARKER;

ANALYTICAL EQUIPMENT; BIOLOGICAL MONITORING; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION MATRIX BASED PLATFORM; CELL ASSAY; CELL COUNTING; CELL ISOLATION; CIRCULATING TUMOR CELL; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; FIELD FLOW FRACTIONATION; FILTER; FUNCTIONALIZED NANODETECTOR; GENETIC ANALYSIS; HUMAN; IMMUNOASSAY; IMMUNOMAGNETIC BEAD; IMMUNOMAGNETIC BEAD BASED CIRCULATING TUMOR CELL DETECTION TECHNOLOGY; IMMUNOMAGNETIC SEPARATION; LABORATORY DEVICE; LASER SCANNING CYTOMETER; METASTASIS; MICROFILTRATION; MICROFLUIDIC ANALYSIS; MICROFLUIDIC INERTIAL FOCUSING CHIP; MICROFLUIDIC MICROPOSTS CHIP; MICROFLUIDIC MIXING CHIP; NON INVASIVE MEASUREMENT; NUCLEIC ACID ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR BIOPSY; ANDROGEN RECEPTOR GENE; CELL COUNT; CELL STRUCTURE; DNA MODIFICATION; ENRICHMENT CULTURE; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; INTRACELLULAR SIGNALING; MICROFLUIDICS; MOLECULAR GENETICS; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN EXPRESSION;

HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84903523860     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.82     Document Type: Review

References (89)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
2. Kantoff, P. W. et al. Sipuleucel T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
3. de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376, 1147-1154 (2010).
4. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
5. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
6. Parker, C. et al. Alpha emitter radium 223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213-223 (2013).
7. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
8. Scher, H. I., Morris, M. J., Larson, S. & Heller, G. Validation and clinical utility of prostate cancer biomarkers. Nat. Rev. Clin. Oncol. 10, 225-234 (2013).
9. Halabi, S. et al. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J. Clin. Oncol. 31, 3944-3950 (2013).
10. Pantel, K., Alix-Panabieres, C. & Riethdorf, S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 6, 339-351 (2009).
11. Yu, M., Stott, S., Toner, M., Maheswaran, S. & Haber, D. A. Circulating tumor cells: Approaches to isolation and characterization. J. Cell. Biol. 192, 373-382 (2011).
12. Fehm, T. et al. Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin. Cancer Res. 8, 2073-2084 (2002).
13. Heitzer, E. et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 73, 2965-2975 (2013).
14. Alix-Panabieres, C. & Pantel, K. Circulating tumor cells: Liquid biopsy of cancer. Clin. Chem. 59, 110-118 (2013).
15. Heitzer, E., Auer, M., Ulz, P., Geigl, J. B. & Speicher, M. R. Circulating tumor cells and DNA as liquid biopsies. Genome Med. 5, 73 (2013).
16. Saylor, P. J., Lee, R. J. & Smith, M. R. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J. Clin. Oncol. 29, 3705-3714 (2011).
17. Scher, H. I., Morris, M. J., Kelly, W. K., Schwartz, L. H. & Heller, G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin. Cancer Res. 11, 5223-5232 (2005).
18. Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148-1159 (2008).
19. Jadvar, H. et al. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J. Nucl. Med. 54, 1195-1201 (2013).
20. Jadvar, H. et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin. Nucl. Med. 37, 637-643 (2012).
21. Mosavi, F. et al. Whole-body diffusion-weighted MRI compared with 18F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am. J. Roentgenol. 199, 1114-1120 (2012).
22. Yu, E. Y. et al. C11-Acetate and F 18 FDG PET for men with prostate cancer bone metastases: Relative findings and response to therapy. Clin. Nucl. Med. 36, 192-198 (2011).
23. Brown, M. S. et al. Computer-Aided quantitative bone scan assessment of prostate cancer treatment response. Nucl. Med. Commun. 33, 384-394 (2012).
24. Lee, R. J. et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin. Cancer Res. 19, 3088-3094 (2013).
25. Fleming, M. T., Morris, M. J., Heller, G. & Scher, H. I. Post-Therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat. Clin. Pract. Oncol. 3, 658-667 (2006).
26. Smith, D. C. et al. Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J. Clin. Oncol. 31, 412-419 (2013).
27. Ellinger, J. et al. The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol. Oncol. 29, 124-129 (2011).
28. Schwarzenbach, H. et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res. 15, 1032-1038 (2009).
29. Dawson, S. J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013).
30. Ashworth, T. R. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust. Med. J. 14, 146-149 (1869).
31. Parkinson, D. R. et al. Considerations in the development of circulating tumor cell technology for clinical use. J. Transl. Med. 10, 138 (2012).
32. Ni, J. et al. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev. 31, 779-791 (2012).
33. Gorges, T. M. et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial to mesenchymal transition. BMC Cancer 12, 178 (2012).
34. Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580-584 (2013).
35. Bitting, R. L. et al. Development of a method to isolate circulating tumor cells using mesenchymal-based capture. Methods 64, 129-136 (2013).
36. Ozkumur, E. et al. Inertial focusing for tumor antigen-dependent and-independent sorting of rare circulating tumor cells. Sci. Transl. Med. 5, 179ra47 (2013).
37. Veridex, LLC CellSearch™ Circulating Tumor Cell Kit. Premarket notification-expanded indications for use-metastatic prostate cancer [online], http://www.accessdata.fda.gov/cdrh-docs/pdf7/K073338.pdf (2008).
38. Danila, D. C. et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13, 7053-7058 (2007).
39. de Bono, J. S. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14, 6302-6309 (2008).
40. Scher, H. I. et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol. 10, 233-239 (2009).
41. Goodman, O. B. Jr et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol. Biomarkers Prev. 18, 1904-1913 (2009).
42. Gasch, C. et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin. Chem. 59, 252-260 (2013).
43. Kraan, J. et al. External quality assurance of circulating tumor cell enumeration using the CellSearch®system: A feasibility study. Cytometry B Clin. Cytom. 80, 112-118 (2011).
44. Ligthart, S. T. et al. Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS ONE 6, e27419 (2011).
45. Ligthart, S. T. et al. Circulating tumor cells count and morphological features in breast, colorectal and prostate cancer. PLoS ONE 8, e67148 (2013).
46. Todenhofer, T. et al. Preliminary experience on the use of the Adnatest®system for detection of circulating tumor cells in prostate cancer patients. Anticancer Res. 32, 3507-3513 (2012).
47. Talasaz, A. H. et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc. Natl Acad. Sci. USA 106, 3970-3975 (2009).
48. Cann, G. M. et al. mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS ONE 7, e49144 (2012).
49. Powell, A. A. et al. Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 7, e33788 (2012).
50. Casavant, B. P. et al. The VerIFAST: An integrated method for cell isolation and extracellular/intracellular staining. Lab Chip 13, 391-396 (2013).
51. Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235-1239 (2007).
52. Stott, S. L. et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl Acad. Sci. USA 107, 18392-18397 (2010).
53. Lu, Y. T. et al. NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods 64, 144-152 (2013).
54. Kirby, B. J. et al. Functional characterization of circulating tumor cells with a prostate cancer specific microfluidic device. PLoS ONE 7, e35976 (2012).
55. Casavant, B. P. et al. A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods 64, 137-143 (2013).
56. Alix-Panabieres, C. et al. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin. Chem. 51, 1538-1541 (2005).
57. Paris, P. L. et al. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett. 277, 164-173 (2009).
58. Friedlander, T. W. et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int. J. Cancer 134, 2284-2293 (2014).
59. Gascoyne, P. R., Noshari, J., Anderson, T. J. & Becker, F. F. Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 30, 1388-1398 (2009).
60. Gupta, V. et al. ApoStream™, a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood. Biomicrofluidics 6, 24133 (2012).
61. Vona, G. et al. Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulating tumor cells. Am. J. Pathol. 156, 57-63 (2000).
62. Xu, T., Lu, B., Tai, Y. C. & Goldkorn, A. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res. 70, 6420-6426 (2010).
63. Lin, H. K. et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin. Cancer Res. 16, 5011-5018 (2010).
64. Chen, C. L. et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate 73, 813-826 (2013).
65. Coumans, F. A., van Dalum, G., Beck, M. & Terstappen, L. W. Filter characteristics influencing circulating tumor cell enrichment from whole blood. PLoS ONE 8, e61770 (2013).
66. Lazar, D. C. et al. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate tumor derived LNCaP cell line. Phys. Biol. 9, 016002 (2012).
67. Farace, F. et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br. J. Cancer 105, 847-853 (2011).
68. Huang, C., Liu, H., Bander, N. H. & Kirby, B. J. Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system. Biomed. Microdevices 15, 941-948 (2013).
69. Danila, D. C. et al. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur. Urol. 65, 1191-1197 (2014).
70. Cho, E. H. et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys. Biol. 9, 016001 (2012).
71. Marrinucci, D. et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys. Biol. 9, 016003 (2012).
72. Pachmann, K. et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin. Chem. Lab. Med. 43, 617-627 (2005).
73. Saucedo-Zeni, N. et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int. J. Oncol. 41, 1241-1250 (2012).
74. Stott, S. L. et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci. Transl. Med. 2, 25ra23 (2010).
75. Allard, W. J. et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897-6904 (2004).
76. Cristofanilli, M. et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351, 781-791 (2004).
77. Scher, H. I. et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU AA 301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract]. J. Clin. Oncol. 29 (Suppl.), LBA4517 (2011).
78. Attard, G. et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 69, 2912-2918 (2009).
79. Danila, D. C. et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol. 60, 897-904 (2011).
80. Leversha, M. A. et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin. Cancer Res. 15, 2091-2097 (2009).
81. Jiang, Y., Palma, J. F., Agus, D. B., Wang, Y. & Gross, M. E. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin. Chem. 56, 1492-1495 (2010).
82. Magbanua, M. J. et al. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 12, 78 (2012).
83. Darshan, M. S. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71, 6019-6029 (2011).
84. Scher, H. I. & Sawyers, C. L. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23, 8253-8261 (2005).
85. Brown, R. S. et al. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J. Pathol. 198, 237-244 (2002).
86. Miyamoto, D. T. et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2, 995-1003 (2012).
87. Evans, M. J. et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc. Natl Acad. Sci. USA 108, 9578-9582 (2011).
88. Noss, K. R., Wolfe, S. A. & Grimes, S. R. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene 285, 247-256 (2002).
89. Wright, G. L. Jr et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48, 326-334 (1996).